Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
4.320
-0.200 (-4.42%)
Mar 30, 2026, 4:00 PM EDT - Market closed
Cybin Employees
Cybin had 50 employees as of March 31, 2025. The number of employees did not change compared to the previous year.
Employees
50
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,464,346
Market Cap
216.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 50 | 0 | - |
| Mar 31, 2024 | 50 | 0 | - |
| Mar 31, 2023 | 50 | 0 | - |
| Mar 31, 2022 | 50 | 12 | 31.58% |
| Mar 31, 2021 | 38 | 37 | 3,700.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| C4 Therapeutics | 104 |
| Alector | 103 |
| OmniAb | 89 |
| Editas Medicine | 87 |
| Keros Therapeutics | 78 |
| Enlivex | 71 |
| Camp4 Therapeutics | 48 |
| Eledon Pharmaceuticals | 33 |
HELP News
- 18 days ago - Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - GlobeNewsWire
- 24 days ago - Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript - Seeking Alpha
- 25 days ago - Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga
- 25 days ago - Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - GlobeNewsWire
- 4 weeks ago - HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
- 4 weeks ago - Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - GlobeNewsWire
- 5 weeks ago - Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - GlobeNewsWire
- 6 weeks ago - HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - GlobeNewsWire